Shares of CureVac (NASDAQ:CVAC - Get Free Report) were up 3.6% during trading on Friday . The stock traded as high as $3.19 and last traded at $3.16. Approximately 170,744 shares traded hands during mid-day trading, a decline of 79% from the average daily volume of 811,117 shares. The stock had previously closed at $3.05.
Analyst Ratings Changes
Separately, JMP Securities reissued a "market outperform" rating and set a $16.00 target price on shares of CureVac in a report on Monday, September 16th.
Read Our Latest Research Report on CureVac
CureVac Stock Performance
The firm has a fifty day moving average of $2.86 and a 200 day moving average of $3.13. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.20 and a quick ratio of 6.19. The stock has a market capitalization of $709.70 million, a price-to-earnings ratio of 5.76, a price-to-earnings-growth ratio of 0.24 and a beta of 2.59.
Institutional Investors Weigh In On CureVac
Hedge funds and other institutional investors have recently made changes to their positions in the company. Private Advisor Group LLC purchased a new stake in CureVac during the third quarter worth $30,000. International Assets Investment Management LLC acquired a new position in shares of CureVac in the third quarter worth about $35,000. Integrated Wealth Concepts LLC purchased a new stake in shares of CureVac during the 3rd quarter worth about $35,000. Bank of New York Mellon Corp acquired a new stake in shares of CureVac during the 2nd quarter valued at about $54,000. Finally, Ballentine Partners LLC increased its stake in shares of CureVac by 58.6% in the 3rd quarter. Ballentine Partners LLC now owns 22,755 shares of the company's stock valued at $67,000 after purchasing an additional 8,406 shares in the last quarter. Institutional investors and hedge funds own 17.26% of the company's stock.
CureVac Company Profile
(
Get Free Report)
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.
Recommended Stories
Before you consider CureVac, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CureVac wasn't on the list.
While CureVac currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
